MINI FUTURE LONG - ZEALAND PHARMA | Market Closed - Börse Stuttgart 12:29:17 18/05/2024 am IST | ||
| 3.07 EUR | -5.54% |
|
| Current month | -13.03% | ||
| 1 month | -0.97% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 3.07 | -5.54% |
| 16/24/16 | 3.25 | -13.33% |
| 15/24/15 | 3.75 | +6.53% |
| 14/24/14 | 3.52 | +3.83% |
| 13/24/13 | 3.39 | -8.13% |
Delayed Quote Börse Stuttgart
Last update May 18, 2024 at 12:29 am IST
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | ME731L |
| ISIN | DE000ME731L8 |
| Date issued | 17/01/2024 |
| Strike | 364.1 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.02 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.44 € |
|---|---|
| Lowest since issue | 1.05 € |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
600
DKK
Average target price
785.6
DKK
Spread / Average Target
+30.93%
- Stock Market
- Certificates
- Certificat
